Track record · closed signal

AbbVie Inc. (ABBV) — closed signal from January 27, 2026

Partial Published before the outcome was known, scored automatically when the window closed on April 27, 2026.

Predicted vs. what happened

ABBV price · publication thesis → realized outcomesplit-adjusted
$222.93 Published $245.22 Target $198.71 Window close $237.11 Peak
$218.00 – $226.00Entry zone — fair-value band
$222.93Published — price the day we called it
$245.22Target — the price the thesis aimed for
$237.11Peak — highest point inside the window, not a realized return
$198.71Window close — end-of-window price, context only

What happened

Partial

Reached 64% of the predicted growth at its peak, without hitting the target.

Peak price
$237.11
peak on March 4, 2026 — not a realized return
Peak gain
+6.4%
peak, from the publication price
Window close
$198.71
end-of-window price, context only
Days to target
—
Window
January 27, 2026 – April 27, 2026

The thesis — published January 27, 2026

Predicted growth
+10%
over the measurement window
Target price
$245.22
the price the thesis aimed for
Entry zone
$218.00 – $226.00
the fair-value band we waited for
Price at publication
$222.93
published January 27, 2026
Confidence
71%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

AbbVie is a relatively safe stock for the next few months and also has a clear growth story: analysts raised the price target because its key drugs Skyrizi and Rinvoq keep selling well. That makes it a candidate to buy gradually on price drops, though it could lag if investors shift money to faster-growing sectors or if drug news causes sudden moves.

Primary drivers

  • Analyst backing supports the story of improving drug sales and momentum
  • Stable earnings make the stock steadier in choppy markets
  • Big company size makes it easy to trade between short and core holdings
  • If confidence in its drug pipeline grows, the stock could be valued higher

How it played out

ABBV: thesis partly played out but target was missed

Lyra published ABBV at $222.93 on 2026-01-27 with a short-term 10% expected gain. The thesis pointed to analyst backing, steady earnings, easy trading in a large company, and possible higher valuation if confidence in the drug pipeline grew. It also cited Skyrizi and Rinvoq sales as part of the growth story.

Inside the window, ABBV rose to a $237.11 peak on 2026-03-04, a 6.4% gain. It stayed below the $245.22 target and never reached it. By 2026-04-27, it ended at $198.71. The thesis partly played out early, then missed by the close.

What happened during the window

On February 4, 2026, AbbVie reported fourth-quarter revenue of $16.62 billion and adjusted earnings of $2.71 per share. The report said Skyrizi revenue rose 32.5% and Rinvoq revenue rose 29.5%.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All ABBV signals